BioNexus Gene Lab appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics

BioNexus Gene Lab Corp

Dr. Meyyappan appointed CCO of Fidelion effective March 11, 2026; will lead global commercial strategy for VitaGuard MRD platform.
He brings 15+ years experience in oncology diagnostics, previously at Menarini, Congenica, Variantyx, and QIAGEN.
BioNexus holds exclusive commercialization rights for VitaGuard in Southeast Asia through its Fidelion investment.
MRD testing is a fast-growing precision oncology segment for early cancer recurrence detection.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.